Celldex Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
1,005
across all filing types
Latest filing
2026-05-07
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
CLDX
Celldex Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies. The company's research focuses on the intersection of mast cell biology and immunology to treat severe inflammatory, allergic, and autoimmune diseases. Its lead program is barzolvolimab, a humanized monoclonal antibody that inhibits KIT, a receptor tyrosine kinase essential for the function and survival of mast cells. By targeting this core pathological driver, Celldex aims to provide a best-in-class treatment option. The company leverages proprietary antibody programs and technologies supported by in-house discovery and development capabilities to advance its pipeline.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2026-05-07 | English | |
| FORM 8-K | 2026-05-07 | English | |
| Major Shareholding Notification 2026 | 2026-05-06 | English | |
| Major Shareholding Notification 2026 | 2026-04-29 | English | |
| ARS - Celldex Therapeutics, Inc. (0000744218) (Filer) | 2026-04-29 | English | |
| DEF 14A - Celldex Therapeutics, Inc. (0000744218) (Filer) | 2026-04-29 | English |
Browse filings by year
21 years- 2026 15 filings
- 2025 54 filings
- 2024 76 filings
- 2023 47 filings
- 2022 48 filings
- 2021 54 filings
- 2020 54 filings
- 2019 34 filings
- 2018 53 filings
- 2017 75 filings
- 2016 52 filings
- 2015 38 filings
- 2014 43 filings
- 2013 50 filings
- 2012 35 filings
- 2011 39 filings
- 2010 43 filings
- 2009 64 filings
- 2008 84 filings
- 2007 40 filings
- 2006 7 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46085251 | 10-Q | 2026-05-07 | English | ||
| 46085252 | FORM 8-K | 2026-05-07 | English | ||
| 46085248 | Major Shareholding Notification 2026 | 2026-05-06 | English | ||
| 46085249 | Major Shareholding Notification 2026 | 2026-04-29 | English | ||
| 38554698 | ARS - Celldex Therapeutics, Inc. (0000744218) (Filer) | 2026-04-29 | English | ||
| 38550776 | DEF 14A - Celldex Therapeutics, Inc. (0000744218) (Filer) | 2026-04-29 | English | ||
| 46085253 | 424B5 | 2026-04-02 | English | ||
| 33155261 | 8-K - Celldex Therapeutics, Inc. (0000744218) (Filer) | 2026-04-02 | English | ||
| 33149884 | 424B5 - Celldex Therapeutics, Inc. (0000744218) (Filer) | 2026-04-01 | English | ||
| 46085250 | Major Shareholding Notification 2026 | 2026-03-26 | English | ||
| 46085254 | Major Shareholding Notification 2026 | 2026-03-10 | English | ||
| 32880547 | 10-K - CELLDEX THERAPEUTICS, INC. (0000744218) (Filer) | 2026-02-25 | English | ||
| 32880546 | 8-K - CELLDEX THERAPEUTICS, INC. (0000744218) (Filer) | 2026-02-25 | English | ||
| 23506883 | SCHEDULE 13G/A Filing | 2026-02-10 | English | ||
| 18382643 | 4 Filing | 2026-01-06 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Celldex Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31801/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31801 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31801 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31801 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31801}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Celldex Therapeutics, Inc. (id: 31801)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.